Eli Lilly and Regeneron have been selected for a US program aimed at speeding up the review of new manufacturing plants. The program, referred to as the FDA PreCheck pilot, is an initiative to expedite the review process for new manufacturing facilities. The selection of these companies is part of a broader effort by the FDA to launch this pilot program, although some reports suggest the initiative may raise legal questions and concerns.